180 related articles for article (PubMed ID: 31571524)
1. CXCR4-targeted PET imaging using
Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
[No Abstract] [Full Text] [Related]
2.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
3.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
4. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
6. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
7. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
Ngo HT; Leleu X; Lee J; Jia X; Melhem M; Runnels J; Moreau AS; Burwick N; Azab AK; Roccaro A; Azab F; Sacco A; Farag M; Sackstein R; Ghobrial IM
Blood; 2008 Jul; 112(1):150-8. PubMed ID: 18448868
[TBL] [Abstract][Full Text] [Related]
8. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
10. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Roccaro AM; Sacco A; Jimenez C; Maiso P; Moschetta M; Mishima Y; Aljawai Y; Sahin I; Kuhne M; Cardarelli P; Cohen L; San Miguel JF; Garcia-Sanz R; Ghobrial IM
Blood; 2014 Jun; 123(26):4120-31. PubMed ID: 24711662
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
Hartimath SV; van Waarde A; Dierckx RA; de Vries EF
Mol Pharm; 2014 Nov; 11(11):3810-7. PubMed ID: 25094028
[TBL] [Abstract][Full Text] [Related]
12. Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.
Pawnikar S; Miao Y
Future Med Chem; 2020 Jul; 12(13):1213-1225. PubMed ID: 32515227
[No Abstract] [Full Text] [Related]
13. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).
Woodard LE; De Silva RA; Behnam Azad B; Lisok A; Pullambhatla M; G Lesniak W; Mease RC; Pomper MG; Nimmagadda S
Nucl Med Biol; 2014 Aug; 41(7):552-61. PubMed ID: 25038987
[TBL] [Abstract][Full Text] [Related]
14. In vivo validation of
Renard I; Domarkas J; Poty S; Burke BP; Roberts DP; Goze C; Denat F; Cawthorne CJ; Archibald SJ
Nucl Med Biol; 2023; 120-121():108335. PubMed ID: 37068392
[TBL] [Abstract][Full Text] [Related]
15. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
16. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
18. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
19. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
20. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
